Sorry, Your Requested Page Was Not Found.
Greetings! We apologize for the inconvenience, but the page, Press Release Eidos Therapeutics Announces Positive Phase 2 Data For Ag10 In Symptomatic Patients With Mutant Or Wild Type Ttr Amyloid Cardiomyopathy is no longer available. Please use our search box below to find related content and browse the list of related news stories. Depending on the topic, news articles are deleted 3 - 18 months after the created date. We prefer to keep content fresh and current and not keep old news. Thanks for visiting today.Search RobinsPost News & Noticias
Ultragenyx Announces Positive Interim Phase 1/2 Data in Patients with Angelman Syndrome After Treatment with GTX-102
Expansion Cohorts showed rapid, clinically meaningful improvement across multiple domains; improvements consistent or exceeding Dose-escalation ... Read More
Geneos Therapeutics Announces Positive Phase 1/2 Data for GT-30 Trial of Personalized Therapeutic Cancer Vaccine
This historical comparator response rate was modeled on Phase 3 KN-240 data presented at ASCO 2019 and is also consistent with the prior Phase 2 KN-224 ... This press release contains certain ... Read More
Candel Therapeutics Announces Positive Interim Data from Randomized Phase 2 Clinical Trial of CAN-2409 in Non-Metastatic Pancreatic Cancer
April 04, 2024 (GLOBE NEWSWIRE) -- Candel Therapeutics ... to help patients fight cancer, today announced updated interim survival data from the ongoing randomized phase 2 clinical trial of ... Read More
Allyx Therapeutics Announces Positive Phase 1b Multiple Ascending Dose Data and Advances ALX-001 to Patients
Safety of ALX-001 Reinforced by New Data ... Allyx Therapeutics, a clinical-stage biotechnology company, announced that its lead compound, ALX-001, is ready to proceed to Phase 2 clinical developm ... Read More
Silence Therapeutics Announces Positive Topline 36-Week Data from Ongoing Phase 2 Study of Zerlasiran in Patients with High Lipoprotein(a)
Silence Therapeutics plc ... today announced positive topline 36-week data from the ongoing ALPACAR-360 phase 2 study of zerlasiran (SLN360) in 178 subjects with baseline lipoprotein(a), or ... Read More
Roivant announces $1.5B share buyback, positive Phase 2 data
The transaction is expected to close on or about April 4. The company also reported positive data from a Phase 2 study of brepocitinib in the treatment of non-infectious uveitis, or NIU. Read More
Enliven Therapeutics Announces Positive Proof of Concept Data from Phase 1 Clinical Trial of ELVN-001 in Chronic Myeloid Leukemia
Achieved initial cumulative MMR rate of 44% (7/16) by 12 weeks in response-evaluable patients, which compares favorably to precedent Phase 1 trials of ... As a result, the data referenced in this ... Read More
Cybin Announces Positive End-of-Phase 2 Meeting with FDA for CYB003 in Major Depressive Disorder and Phase 3 Program Design
The Company has received minutes from its End-of-Phase-2 meeting ... 75% of patients receiving 16mg of CYB003 achieved remission from depression symptoms. With positive durability data ... Read More
Enliven Therapeutics Announces Positive Proof of Concept Data from Phase 1 Clinical Trial of ELVN-001 in Chronic Myeloid Leukemia
April 11, 2024 (GLOBE NEWSWIRE) -- Enliven Therapeutics ... today announced positive proof of concept data from the Phase 1 clinical trial evaluating ELVN-001 in patients with chronic myeloid ... Read More
Allyx Therapeutics Announces Positive Phase 1b Multiple Ascending Dose Data and Advances ALX-001 to Patients
Two Oral Doses Selected for Further Study in Alzheimer’s and Parkinson’s Disease Patients NEW HAVEN, Conn., March 11, 2024 (GLOBE NEWSWIRE) -- Allyx Therapeutics, a clinical-stage ... Read More
Blow Us A Whistle
Comments (Whistles) Designed By Disqus